検索
NewAmsterdam Pharma Company NV
NAMSウォッチリストに追加
34.660USD
+0.770+2.27%
取引時間 （ET）15分遅れの株価
4.04B時価総額
損失額直近12ヶ月PER
詳細情報 NewAmsterdam Pharma Company NV 企業名
NewAmsterdam Pharma Company NV is a Netherlands based company. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The Company is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The Company is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimer’s disease. The Company strives to offer its products around the world.
NewAmsterdam Pharma Company NVの企業情報
企業コードNAMS
会社名NewAmsterdam Pharma Company NV
上場日Nov 23, 2022
最高経営責任者「CEO」Davidson (Michael Harvey)
従業員数68
証券種類Ordinary Share
決算期末Nov 23
本社所在地Gooimeer 2-35
都市NAARDEN
証券取引所NASDAQ OMX - NASDAQ BASIC
国Netherlands
郵便番号1411 DC
電話番号31352062971
ウェブサイトhttps://ir.newamsterdampharma.com/
企業コードNAMS
上場日Nov 23, 2022
最高経営責任者「CEO」Davidson (Michael Harvey)
NewAmsterdam Pharma Company NVの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. John W. Smither
Mr. John W. Smither
Temporary Non-Executive Independent Director
Temporary Non-Executive Independent Director
2.32K
--
Mr. William H. (Will) Lewis, J.D.
Mr. William H. (Will) Lewis, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
2.32K
--
Mr. Mark C. Mckenna
Mr. Mark C. Mckenna
Independent Director
Independent Director
2.32K
--
Dr. James N. Topper, M.D., Ph.D.
Dr. James N. Topper, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Michael Harvey Davidson, M.D.
Dr. Michael Harvey Davidson, M.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Dr. John Kastelein
Dr. John Kastelein
Chief Scientific Officer, Non-Executive Director
Chief Scientific Officer, Non-Executive Director
--
--
Ms. Juliette Audet
Ms. Juliette Audet
Chief Business Officer
Chief Business Officer
--
--
Dr. Louis Lange, M.D., Ph.D.
Dr. Louis Lange, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Nicholas Downing, M.D.
Dr. Nicholas Downing, M.D.
Director
Director
--
--
Ms. Janneke Van Der Kamp
Ms. Janneke Van Der Kamp
Temporary Non-Executive Director
Temporary Non-Executive Director
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. John W. Smither
Mr. John W. Smither
Temporary Non-Executive Independent Director
Temporary Non-Executive Independent Director
2.32K
--
Mr. William H. (Will) Lewis, J.D.
Mr. William H. (Will) Lewis, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
2.32K
--
Mr. Mark C. Mckenna
Mr. Mark C. Mckenna
Independent Director
Independent Director
2.32K
--
Dr. James N. Topper, M.D., Ph.D.
Dr. James N. Topper, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Michael Harvey Davidson, M.D.
Dr. Michael Harvey Davidson, M.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Dr. John Kastelein
Dr. John Kastelein
Chief Scientific Officer, Non-Executive Director
Chief Scientific Officer, Non-Executive Director
--
--
よくある質問
NewAmsterdam Pharma Company NVの上位5名の株主は誰ですか？
NewAmsterdam Pharma Company NVの上位5名の株主は以下のとおりです。Mr. John W. Smither
NewAmsterdam Pharma Company NV（NAMS）の株式を保有している機関の数はいくつですか？
2026Q1時点で、NewAmsterdam Pharma Company NVの株式を保有している機関は366社あり、保有株式の総市場価値は約128.70Mで、全体の110.09%を占めています。2025Q4と比較して、機関の持ち株は2432976.00増加しています。